

anti-inflammatoty and immuno-therapy - all results

| Treatment | Number of studies | clinical deterioration | clinical improvement | deaths | viral clearance |
|-----------------------------|------------------------|------------------------|----------------------|---|-----------------|
| Immunostimulants drugs | 4 studies ¹ | - | - | 0.87 [0.31 ; 2.41], 2 RCTs, I2=0% inconclusive result | - |
| anti-inflammatory therapies | 2 studies ² | - | - | 0.85 [0.61 ; 1.19], 1 study, I2=0% inconclusive result | - |

Notes

¹PROVENT, 2022 (NCT04625725); BLAZE-2 US (Cohen), 2021 (NCT04497987); Cov-2069 (Cohort A : negative SARS-CoV-2 RT-qPCR test result), 2021 (NCT04452318); Jurdi, 2022 ()

²Gendelman, 2020 (); Chandan, 2020 ()